Beyond monotherapy: sex- and age-stratified pharmacovigilance of blonanserin adverse events focusing on drug-drug interactions
BackgroundBlonanserin is an atypical antipsychotic that has been marketed in several Asian countries, but the drug-drug interaction (DDI) signals between it and commonly co-prescribed medications have not been systematically evaluated.ObjectiveThis study aimed to systematically explore adverse event (AE) signals for blonanserin both as monotherapy and in combination therapies, using the Japanese…
Read original article on Frontiers in Psychiatry | New and Recent Articles →Related news
-
Beyond emotional symptoms: multidomain routine outcome monitoring in psychiatric outpatient care
Switzerland
-
A real diagnosis or just a Western trend? Navigating adult ADHD diagnosis and treatment in Saudi Arabia
Switzerland
-
Psychological safety and organizational silence in Turkish schools
Switzerland
-
Age-stratified reporting patterns of medications and suicide-related events in FAERS
Switzerland
-
Exploring the association between heart rate variability and self-efficacy: A secondary analysis of a cross-sectional pilot study
Switzerland
-
A shared core, distinct network organization: urban–rural variation in ADHD–aggression networks and simulated intervention profiles among Chinese college students
Switzerland
-
A comparison of identity development and mindfulness levels between adolescents with and without non-suicidal self-injury
Switzerland
-
Influence of harm-avoidance traits on anxiety: coping style as a mediator and CK1 gene polymorphism as a moderator
Switzerland